Maximilian Diehn

Maximilian Diehn co-developed the CAPP-Seq and iDES technologies for ultrasensitive ctDNA profiling and has led their clinical application for monitoring lung cancer treatment response during radiation therapy and immunotherapy, achieving detection limits below 0.001 percent variant allele frequency. His research at Stanford has demonstrated that ctDNA dynamics during treatment accurately predict pathological response and survival outcomes, enabling real-time treatment adaptation based on molecular response. His technological innovations have set the standard for ctDNA assay sensitivity and are being adopted in clinical trials worldwide.